Phase II Study Using FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable Pancreatic Cancer
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of FOLFIRINOX combined with Stereotactic Body Radiation Therapy (SBRT) in patients with locally advanced, unresectable pancreatic cancer.
General Information
NCT#: NCT02128100
Study ID: 14.0413
Trial Phase: Phase II
Trial Sponsor: James Graham Brown Cancer Center
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Stereotactic body radiotherapy (SBRT), Irinotecan, Leucovorin, FOLFIRINOX